Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment, amelioration or prevention of cancer

Earlier this year, our client TOLREMO therapeutics nominated the clinical candidate for a chemical series that was developed together with Symeres. In this article, we spoke with Yorik Bruseker, one of our chemists, who has been involved in the project since it started at Symeres.

Recently published patents around this nomination are WO 2020/127200 A1 and WO 2021/064142 A1

 
 

Development Centres of Excellence Network Lead Optimization Hit Generation Lead Optimization
 
 
 
 
 

Development Centres of Excellence Network Lead Optimization Hit Generation Lead Optimization
 
 
 
Scroll to top